2008-2018年英国全科医疗中心房颤动药物治疗趋势
该研究基于英国初级保健数据库,从2008至2018年每年进行横断面分析,评估房颤患者抗凝、心率控制及节律控制药物的处方比例变化。结果显示抗凝比例从45.3%升至71.1%,心率控制药物比例稳定在约70%,而全科医生处方的节律控制药物从9.5%降至5.4%。
要点
- 抗凝治疗比例显著增加,主要由非维生素K拮抗剂口服抗凝药驱动。
- 心率控制药物处方比例保持稳定,β受体阻滞剂使用增多而地高辛减少。
- 全科医生节律控制药物处方比例持续下降,可能与疗效安全性顾虑及消融可及性提高有关。
核心结论
- 房颤患者抗凝比例增加与指南推荐相关,并与死亡率和卒中结局改善相关。
- 心率控制中β受体阻滞剂较地高辛更受青睐,全科医生节律控制药物处方下降。
研究设计与样本
- 分析对象为房颤患者,评估抗凝、节律控制和心率控制药物的处方比例。
主要发现
- 抗凝比例从2008年45.3%(95%CI 45.0%至45.7%)升至2018年71.1%(95%CI 70.7%至71.5%)。
- 心率控制药物比例从69.3%(95%CI 68.9%至69.6%)变为71.6%(95%CI 71.2%至71.9%)。
- 全科医生节律控制治疗比例从9.5%(95%CI 9.3%至9.7%)降至5.4%(95%CI 5.2%至5.6%)。
临床怎么用
- 应遵循指南为房颤患者适当增加抗凝治疗,尤其是卒中高危患者。
- 心率控制可优先考虑β受体阻滞剂而非地高辛。
- 全科医生节律控制药物处方下降,需关注消融等非药物节律控制途径的合理转诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The pharmacological management of atrial fibrillation (AF) comprises anticoagulation, for stroke prophylaxis, and rate or rhythm control drugs to alleviate symptoms and prevent heart failure. The aim of this study was to investigate trends in the proportion of patients with AF prescribed pharmacological therapies in the UK between 2008 and 2018. METHODS: Eleven sequential cross-sectional analyses were performed yearly from 2008 to 2018. Data were derived from an anonymised UK primary care database. Outcomes were the proportion of patients with AF prescribed anticoagulants, rhythm and rate control drugs in the whole cohort, those at high risk of stroke and those with coexisting heart failure. RESULTS: Between 2008 and 2018, the proportion of patients prescribed anticoagulants increased from 45.3% (95% CI 45.0% to 45.7%) to 71.1% (95% CI 70.7% to 71.5%) driven by increased prescription of non-vitamin K antagonist anticoagulants. The proportion of patients prescribed rate control drugs remained constant between 2008 and 2018 (69.3% (95% CI 68.9% to 69.6%) to 71.6% (95% CI 71.2% to 71.9%)). The proportion of patients prescribed rhythm control therapy by general practitioners (GPs) decreased from 9.5% (95% CI 9.3% to 9.7%) to 5.4% (95% CI 5.2% to 5.6%). CONCLUSIONS: There has been an increase in the proportion of patients with AF appropriately prescribed anticoagulants following National Institute for Health and Care Excellence and European Society of Cardiology guidelines, which correlates with improvements in mortality and stroke outcomes. Beta-blockers appear increasingly favoured over digoxin for rate control. There has been a steady decline in GP prescribing rates for rhythm control drugs, possibly related to concerns over efficacy and safety and increased availability of AF ablation.
引用
- Phillips K, Subramanian A, Thomas GN, et al. Trends in the pharmacological management of atrial fibrillation in UK general practice 2008-2018. Heart. 2021. PMID: 34226195. doi:10.1136/heartjnl-2021-319338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。